Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Waters

Showing results (111-120 of 157) with videos related to

Pageof 16
Sort By:
Pharmacoeconomics|December 18, 2009
Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the USVirginia M Rosen, Douglas C A Taylor, Hemangi Parekh, et al.
The American Journal of Cardiology|March 29, 2011
Reaching C-reactive protein and low-density lipoprotein cholesterol goals in dyslipidemic patients (from the Lipid Treatment Assessment Project [L-TAP] 2)Cheng-Wen Chiang, Raul D Santos, David D Waters, et al.
Circulation|August 27, 2003
Differences in medical care and disease outcomes among black and white women with heart diseaseAshish K Jha, Paul D Varosy, Alka M Kanaya, et al.
Journal of the American College of Cardiology|April 2, 2011
Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trialsDavid D Waters, Jennifer E Ho, David A DeMicco, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 18, 2008
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristicsRoy W Jones, Miia Kivipelto, Howard Feldman, et al.
Journal of the American College of Cardiology|November 7, 2006
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) studyDavid D Waters, John C LaRosa, Philip Barter, et al.
Circulation|April 6, 2018
Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT TrialAntonio J Vallejo-Vaz, Rana Fayyad, S Matthijs Boekholdt, et al.
The American Journal of Cardiology|March 31, 2012
Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study)Jennifer E Ho, David D Waters, Allison Kean, et al.
Journal of the American College of Cardiology|May 17, 2008
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgerySanjiv J Shah, David D Waters, Philip Barter, et al.
The American Journal of Cardiology|March 4, 2014
Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL)Benoit J Arsenault, S Matthijs Boekholdt, Samia Mora, et al.
Pageof 16

Showing results (111-120 of 157) with videos related to

Sort By:
Pageof 16
Pharmacoeconomics|December 18, 2009
Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the USVirginia M Rosen, Douglas C A Taylor, Hemangi Parekh, et al.
The American Journal of Cardiology|March 29, 2011
Reaching C-reactive protein and low-density lipoprotein cholesterol goals in dyslipidemic patients (from the Lipid Treatment Assessment Project [L-TAP] 2)Cheng-Wen Chiang, Raul D Santos, David D Waters, et al.
Circulation|August 27, 2003
Differences in medical care and disease outcomes among black and white women with heart diseaseAshish K Jha, Paul D Varosy, Alka M Kanaya, et al.
Journal of the American College of Cardiology|April 2, 2011
Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trialsDavid D Waters, Jennifer E Ho, David A DeMicco, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 18, 2008
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristicsRoy W Jones, Miia Kivipelto, Howard Feldman, et al.
Journal of the American College of Cardiology|November 7, 2006
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) studyDavid D Waters, John C LaRosa, Philip Barter, et al.
Circulation|April 6, 2018
Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT TrialAntonio J Vallejo-Vaz, Rana Fayyad, S Matthijs Boekholdt, et al.
The American Journal of Cardiology|March 31, 2012
Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study)Jennifer E Ho, David D Waters, Allison Kean, et al.
Journal of the American College of Cardiology|May 17, 2008
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgerySanjiv J Shah, David D Waters, Philip Barter, et al.
The American Journal of Cardiology|March 4, 2014
Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL)Benoit J Arsenault, S Matthijs Boekholdt, Samia Mora, et al.
Pageof 16